The impact of omalizumab treatment in UK clinical practice Asthma Patient Experience on Xolair (Omalizumab) (the APEX II study)

Trial Profile

The impact of omalizumab treatment in UK clinical practice Asthma Patient Experience on Xolair (Omalizumab) (the APEX II study)

Completed
Phase of Trial: Phase IV

Latest Information Update: 02 Dec 2015

At a glance

  • Drugs Omalizumab (Primary)
  • Indications Allergic asthma
  • Focus Therapeutic Use
  • Acronyms APEX-II
  • Sponsors Novartis Pharmaceuticals
  • Most Recent Events

    • 10 Sep 2014 Interim results presented at the 24th Annual Congress of the European Respiratory Society
    • 01 Aug 2013 Status changed from recruiting to completed as reported by ISRCTN: Current Controlled Trials record.
    • 17 May 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top